N-(6-methyl-pyridin-2-yl)-nicotinamide | 57646-70-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: N-(6-methyl-pyridin-2-yl)-nicotinamide
• 英文别名: N-(6-methylpyridin-2-yl)pyridine-3-carboxamide
• CAS: 57646-70-5
• 化学式: C₁₂H₁₁N₃O
• mdl: MFCD00455900
• 分子量: 213.239
• InChiKey: VYMSCFQPFSTNRJ-UHFFFAOYSA-N

物化性质

• 熔点：
  140-141 °C(Solv: ethanol (64-17-5))
• 沸点：
  291.5±30.0 °C(Predicted)
• 密度：
  1.246±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.083
• 拓扑面积：
  54.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-氨基-6-甲基吡啶 、 烟酰氯 在 吡啶 作用下， 反应 1.0h， 生成 N-(6-methyl-pyridin-2-yl)-nicotinamide
  参考文献：
  名称：

  Design and synthesis of noncompetitive metabotropic glutamate receptor subtype 5 antagonists

  摘要：

  A series of diaryl amides was designed and synthesized as novel nonethynyl mGluR5 antagonists. The systematic variation of the pharmacophoric groups led to the identification of a lead compound that demonstrated micromolar affinity for the mGluR5. Further optimization resulted in compounds with improved binding affinities and antagonist profiles, in vitro. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.04.032

文献信息

• 1H and 13C NMR spectral studies of conformation of some N-(2-pyridinyl)-3-pyridinecarboxamides
  作者：Netai C. Singha、D.N. Sathyanarayana

  DOI：10.1016/s0022-2860(98)00365-2

  日期：1998.8

  spectra, NOE experiments and MINDO/3 calculations. In dilute solutions, the 2-pyridyl ring is coplanar with the amide group while the 3-pyridyl ring is apparently not. Compounds 1-3 dimerize through cooperative hydrogen bonding in con-centrated $CDCI_3$ solution (approximately 0.1 M) and the structure of the dimer resembles some of the DNA base-pairs. Hydrogen bonding between N-H and the solvent molecules

  N-(2-吡啶基)-、N-(4-甲基2-吡啶基)-和N-(6-甲基-2-吡啶基)-3的$^IH$和$^13}C$ NMR谱使用 COSY、HETCOR、化学位移和耦合常数相关性分析了不同溶剂中的 -吡啶甲酰胺（分别为 1-3）和 3-吡啶甲酰胺（4）。1-4的构象已经通过利用NMR光谱、NOE实验和MINDO/3计算获得。在稀溶液中，2-吡啶环与酰胺基共面，而3-吡啶环显然不是。化合物 1-3 通过在浓缩 $CDCI_3$ 溶液（约 0.1 M）中的协同氢键形成二聚体，并且二聚体的结构类似于一些 DNA 碱基对。NH 和溶剂分子之间的氢键阻碍了 $(CD_3)_2CO$ 和 $CD_3CN$ 中的二聚化。
• IDO Inhibitors
  申请人：Mautino Mario

  公开号：US20110053941A1

  公开（公告）日：2011-03-03

  Presently provided are methods for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of a compound as described in one of the aspects described herein; (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound as described in one of the aspects described herein; (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; and (f) treating immunosuppression associated with an infectious disease, e.g., HIV-I infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount a compound as described in one of the aspects described herein.

  目前提供以下方法：(a) 通过接触本文中描述的化合物的调节有效量与吲哚胺2,3-二氧化酶相互作用，从而调节吲哚胺2,3-二氧化酶的活性；(b) 治疗需要吲哚胺2,3-二氧化酶(IDO)介导的免疫抑制的患者，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(c) 治疗需要抑制吲哚胺-2,3-二氧化酶酶活性的医疗状况，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(d) 增强抗癌治疗的有效性，包括给予抗癌剂和本文中描述的化合物；(e) 治疗与癌症相关的肿瘤特异性免疫抑制，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(f) 治疗与传染病相关的免疫抑制，例如HIV-1感染，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量。
• Benzothiazole derivatives as DYRK1 inhibitors
  申请人：PHARMASUM THERAPEUTICS AS

  公开号：US10927106B2

  公开（公告）日：2021-02-23

  The present invention relates to compounds of Formula (I), which are DYRK1A and/or DYRK1B inhibitors, and their use in the treatment of neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), metabolic disorders such as Metabolic Syndrome or diabetes mellitus, and cancer.

  本发明涉及作为 DYRK1A 和/或 DYRK1B 抑制剂的式 (I) 化合物及其在治疗神经退行性疾病（如阿尔茨海默病 (AD) 和帕金森病 (PD)）、代谢性疾病（如代谢综合征或糖尿病）和癌症中的用途。
• BINIECKI S.; MODRZEJEWSKA W., ACTA POL. PHARM. <APPH-AX>, 1975, 32, NO 3, 269-272
  作者：BINIECKI S.、 MODRZEJEWSKA W.

  DOI：——

  日期：——
• 1H-PYRROLO(3,2-B)PYRIDINE-3-CARBOXYLIC ACID AMIDES
  申请人：Neurogen Corporation

  公开号：EP1453831A1

  公开（公告）日：2004-09-08